Launching 4 New Products during Stage 2 and Increasing the New Drug Mix

「As a result of active sales activities to maximize the new-drug mix, the new-drug mix was 55.4%, exceeding the target of 50% or higher, and sales were ¥57 billion, exceeding the target of ¥56 billion.」

「Kyorin Pharmaceutical Co., Ltd. has made maximizing the new-drug mix one of the key strategies of its medium-term management plan, and its sales division is pursuing active activities to maximize new-drug adoption.」

「The medium-term management plan identifies maximizing the new-drug mix as one of its business strategies. In fiscal 2024, the company aims to maximize new-drug adoption by devoting maximum effort to accelerating growth in 5 new products.」

「Kyorin Pharmaceutical Co., Ltd. has made maximizing the new-drug mix one of the key strategies of its medium-term management plan, and its sales division is pursuing active activities to maximize new-drug adoption.」

「Kyorin Pharmaceutical Co., Ltd. has made maximizing the new-drug mix a key strategy of its medium-term management plan. In the fiscal year ending March 2024, it is pursuing active business activities under its divisional policy of “maximizing new-drug adoption through solution-based sales,” meaning proposals that address customer needs.」

「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew,」

「The core products Beova, a treatment for overactive bladder, and Desalex, an allergy treatment, grew. However, Lasvic Tablets, a quinolone oral antibacterial drug newly launched in January 2020, continued to face challenges in market penetration because of the suspension of MR activities at medical institutions and other factors.」

「To improve the new-drug mix, the company launched Desalex, a long-acting selective H1-receptor antagonist and treatment for allergic diseases; Beova, a selective β3-adrenergic receptor agonist for overactive bladder; and Lasvic tablets, an oral quinolone antibacterial. Under the new medium-term management plan, “HOPE100—Stage 3—,” the company will devote maximum effort to creating a market for this new-drug portfolio together with Flutiform, a combination treatment for asthma, and achieving a growth trend.」

「Sales of Beova, a selective β3-adrenergic receptor agonist for overactive bladder whose long-term prescribing became possible from December 2019 following the removal of restrictions on the prescription period for new pharmaceuticals, also significantly exceeded the same period of the previous year.」

「To achieve the medium-term management plan’s key strategy of improving the new-drug mix, the company worked to maximize adoption of its core products. Flutiform, a combination treatment for asthma, grew steadily, and sales of Beova, a selective β3-adrenergic receptor agonist for overactive bladder launched in November 2018, also increased.」

「During the first quarter of the consolidated cumulative period, the company worked to maximize adoption of its core products in line with the medium-term management plan’s key strategy of improving the new-drug mix. Flutiform, a combination treatment for asthma, grew steadily, and sales of Beova, a selective β3-adrenergic receptor agonist for overactive bladder launched in November 2018, also increased.」

「Going forward, together with Flutiform, its core combination treatment for asthma, the company will work to create a market for its new-drug portfolio and devote maximum effort to establishing a growth trajectory.」

「During the third quarter of the consolidated cumulative period, the company worked to maximize adoption of its core products in line with the medium-term management plan’s key strategy of improving the new-drug mix,」

「During the second quarter of the consolidated cumulative period, the company worked to maximize adoption of its core products, Flutiform, a combination treatment for asthma, and Desalex, a treatment for allergic diseases, in line with the medium-term management plan’s key strategy of improving the new-drug mix, and both products grew.」

「During the first quarter of the consolidated cumulative period, the company worked to maximize adoption of its core products, in line with the medium-term management plan’s key strategy of improving the new-drug mix, including Flutiform, a core combination treatment for asthma, and Desalex, a treatment for allergic diseases.」

「Significant improvement in the new-drug mix through maximizing adoption of new-drug products」

「To achieve the improvement in the new-drug mix, a key strategy of the medium-term management plan, the company worked to maximize adoption of its core products and accelerate the adoption of new products.」

「To improve the new-drug mix, a key strategy of the medium-term management plan, the company worked to maximize adoption of its core products and accelerate the uptake of new products.」

「To increase the proportion of new drugs, we aim to launch 4 new products during Stage 2 and maximize product uptake together with Flutiform, an asthma combination therapy that has already been launched.」